timothy sykes logo
RVMD Stock Extends Run As Analysts Hike Price Targets Thumbnail
ADD US ONG Google News

RVMD Stock Extends Run As Analysts Hike Price Targets

MATT MONACO•UPDATED APR. 13, 2026, 11:32 AM ET
Reviewed by Jack Kellogg Fact-checked by Tim Sykes

Revolution Medicines Inc – Ordinary Shares soar as pivotal clinical trial advances drive bullish sentiment; stocks have been trading up by 35.05 percent

Candlestick Chart

Live Update At 11:32:24 EDT: On Monday, April 13, 2026 Revolution Medicines Inc – Ordinary Shares stock [NASDAQ: RVMD] is trending up by 35.05%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RVMD has been trading like a momentum biotech, not a sleepy lab story. Over the last few weeks, Revolution Medicines stock lifted from the low $90s to recent closes above $130, a sharp move that lines up with bullish analyst calls and trial progress. The daily chart shows a steady grind higher from $92–$100 into a spike day where RVMD opened near $132, hit $135.81, dipped to $127, and still closed at $130.25. That kind of range tells traders there is real emotion in this tape.

Intraday, RVMD has been a textbook high-volatility play. Pre-market swings from sub-$100 up toward $146.58, then a reset into the $120s–$130s, show why disciplined trading plans matter. Volume and wide candles signal active day and swing trading interest.

Fundamentally, Revolution Medicines remains a classic development-stage biotech. The latest quarter shows roughly -$364.9M in net loss and heavy R&D spend near $294.9M. Margins are deeply negative and returns on equity and assets are in the red. But RVMD holds about $2.03B in cash and short-term investments, a hefty current ratio near 7, and minimal debt, giving the company time to chase daraxonrasib’s potential. For traders, that cash runway plus late-stage catalysts is the core of the RVMD story.

Why Traders Are Watching RVMD’s Daraxonrasib Story

Revolution Medicines has turned RVMD into a focal point for biotech traders because the story checks three big boxes: late-stage data coming soon, strong analyst backing, and a platform that goes beyond one narrow niche.

First, the analyst backdrop. Jefferies stepped up with a Buy rating and a price target raised to $140 from $88, anchored on RVMD’s RAS(ON) platform and its lead asset, daraxonrasib. They are not just optimistic; they are signaling real conviction that the Phase 3 RASolute 302 trial in second-line pancreatic cancer is likely to succeed at the first interim analysis. That kind of language tends to pull more momentum traders into the name.

Oppenheimer backed that up, keeping an Outperform rating on Revolution Medicines with a $150 target while the stock recently traded around $93. The firm expects daraxonrasib’s pancreatic Phase 3 to read out positively in the first half of the year, with a shot at early stoppage and an H2 regulatory filing. For active traders, that creates a defined catalyst window and a clear narrative: RVMD attempting to sprint from development to potential commercial stage on a single pivotal readout.

At the same time, RVMD is expanding the opportunity set. The company launched RASolute 303, a global Phase 3 trial testing daraxonrasib as monotherapy and with chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma, enrolling patients regardless of RAS genotype. That “all-comers” approach broadens the potential market, and it shows Revolution Medicines is not aiming small.

Add in another late-stage trial where RVMD has already dosed first patients in a global daraxonrasib study for first-line metastatic pancreatic cancer and non-small cell lung cancer, and traders are staring at four registrational shots on goal. Upcoming AACR 2026 data — nine presentations spanning daraxonrasib, zoldonrasib in KRAS G12D NSCLC, and next-generation RAS(ON) work — only heighten the potential for RVMD volatility.

More Breaking News

Conclusion

For traders, RVMD now lives at the intersection of big expectations and big risk. Revolution Medicines is burning cash, posting losses near -$364.9M, and trading at lofty valuation metrics like a price-to-book around 11.7 and eye-popping price-to-sales because revenue remains minimal. The numbers scream “story stock,” not value play. That is exactly the kind of setup momentum traders gravitate toward when the news flow is strong.

Right now, that news flow leans bullish. RVMD has multiple Phase 3 trials running, a broad pancreatic and lung cancer strategy, and upcoming AACR data that could extend the RAS(ON) franchise narrative. Jefferies and Oppenheimer see meaningful upside with targets at $140 and $150, well above recent prices. At the same time, a wave of insider selling from the CEO, R&D chief, COO, and commercialization head reminds traders that management is trimming exposure after a strong run, even while keeping sizable stakes.

This is where discipline matters. As Tim Sykes often says, “The market doesn’t care about your opinion, only your plan and your risk management.” As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.”. RVMD offers a clear catalyst roadmap, intense volatility, and heavy hype around daraxonrasib. For traders using it for educational and research purposes, the key is to respect the chart, define risk around these events, and avoid falling in love with the Revolution Medicines story if the price action turns against them.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading RVMD

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”